– Zilebesiran Met Primary Endpoint Demonstrating Up to 16.7 mmHg Placebo-Adjusted Reduction of 24-Hour Mean Systolic Blood Pressure at Three Months of Treatment –
–...
A technology-first approach to investing money is not new, but the tools in artificial intelligence are giving the business new opportunities to outperform. Jeff...